Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
about
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidationMaraviroc: a review of its use in HIV infection and beyondThe pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenzLack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone.PharmGKB summary: abacavir pathwayPharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patientsHIV associated nephropathy: a treatable condition.The role of therapeutic drug monitoring in treatment of HIV infection.Role of therapeutic drug monitoring for protease inhibitors.Traditional herbal medicine use associated with liver fibrosis in rural Rakai, Uganda.Pharmacokinetic interactions between sildenafil and saquinavir/ritonavirThe pharmacogenomics of HIV therapy.Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patientsPopulation pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.Interactions between recreational drugs and antiretroviral agents.Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Simplified regimens for treating HIV infection and AIDS.P glycoprotein in human immunodeficiency virus type 1 infection and therapy.Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults.St Johns wort increases expression of P-glycoprotein: implications for drug interactionsWeight related differences in the pharmacokinetics of abacavir in HIV-infected patients.Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adultsMinimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patientsSignificant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adultsMedical illness and comorbidities in drug users: implications for addiction pharmacotherapy treatment.Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice.The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patientsLack of clinically significant drug interactions between nevirapine and buprenorphine.Safe Treatment of Seizures in the Setting of HIV/AIDS.Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.
P2860
Q24648578-197D6249-4CBF-40B2-A3F8-6A906031E0F0Q26778504-A42D033E-62FA-4898-98A9-EC3A4E0929A1Q28362277-22282721-D0AE-4508-85DB-DEDF4CB738E6Q32039126-3B9F7DA2-1A77-4C75-9899-FBC32F19FD1CQ32064655-700BFF04-775C-4E04-B5BE-D6455B2BE7E0Q33148910-527890DB-6067-4D0B-B6AA-A6FAF72CB3A5Q33819062-9F80059F-CE18-4D82-BDD3-76AD5777FA91Q33938232-BF3EB989-2358-4BA8-94E7-52F1664C7FFDQ34141845-EBD7F656-62E7-46E5-BFD7-6B4101C39DFAQ34208327-720DD330-E830-4A7E-A895-13F3EA3FD618Q34229283-E99B2FE9-FAB0-41F9-BFA8-236A709DC352Q34284286-1A935FB4-1BAC-42C4-80A1-CC2FFBB47846Q34499508-255ACE84-C3AB-41D3-8E83-D85678908765Q34510087-E88843C4-DB5A-4A01-B8C7-4B79B7E3B21DQ34574033-DD986A6F-8B1E-4133-BE83-59CBB1ADFF8DQ34719821-BB72BED7-1450-4160-A122-B3A21EF62A97Q34721793-D2C9E57B-91FA-44D0-A2CF-FED222EBB84AQ34874414-6407D2D8-8EE1-4092-B1F5-896B09BF7DF0Q35004887-6880DFCA-3597-4276-9646-48046EE11CC4Q35018246-35B2399D-7128-4B02-BD2D-351448A77EE0Q35203402-EEE817ED-0770-4FE4-9EDA-37D840C9C06CQ35718765-8B714532-D5C2-4E7A-97C7-7B9670B99A1DQ35791633-A49CC1DF-A5BB-4F5F-89B0-9576A0D126E3Q35804331-CB85D51D-27F8-4139-A46B-79524B659ED0Q35826691-AA23C32F-B80F-4EA1-B0CF-634A489294BBQ35826943-87F10E9C-0A96-4828-B775-93EF38E6A01AQ35827661-99C56F96-35EC-4D5B-B065-76FDD017FF27Q35873680-D230D4B9-C85E-4935-9CC3-B14C424D0DBAQ35883504-2C394C53-8103-4C3F-82D2-90C99E2A8EACQ36024688-362A0D56-AF85-47B8-98CF-32BEFF0EA8EAQ36300127-F2155028-0DF3-4CBB-9327-30718B3B53E3Q36311018-E20E5FEC-8547-471C-A764-1821D06862C5Q36491759-36935AD3-BA9F-4594-B829-816BFCE88928Q36852528-844E360A-9010-4022-B479-7F639175190CQ36993971-A1997D2B-EC5E-4741-9736-43ABF9A7CA79Q37045349-1F4282E0-4E20-4B0B-9145-628E19C19648Q37096562-3102C3E3-52B2-4313-B18F-7F519C3FAAD1Q37157697-335788C1-42D8-430C-AF3B-84A050EAFF63Q37361492-0D6DFFA6-4A01-47F1-AF51-00F8DF9D4249Q37623297-03322428-DB8E-4490-859C-8212B2AEDAC6
P2860
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pharmacokinetics and potential ...... t patients with HIV infection.
@ast
Pharmacokinetics and potential ...... t patients with HIV infection.
@en
type
label
Pharmacokinetics and potential ...... t patients with HIV infection.
@ast
Pharmacokinetics and potential ...... t patients with HIV infection.
@en
prefLabel
Pharmacokinetics and potential ...... t patients with HIV infection.
@ast
Pharmacokinetics and potential ...... t patients with HIV infection.
@en
P2093
P1476
Pharmacokinetics and potential ...... t patients with HIV infection.
@en
P2093
P304
P356
10.2165/00003088-199936040-00004
P577
1999-04-01T00:00:00Z
P6179
1043571674